Eric Bachman
Executive Director Regeneron Pharmaceuticals
Seminars
Wednesday 22nd July 2026
Chair’s Opening Remarks
8:55 am
Wednesday 22nd July 2026
Roundtable Discussion: Unlocking Therapeutic Opportunity in MMN & GBS Through Improved Understanding of Disease Biology & Timing
3:30 pm
- How can refining diagnosis, prevalence understanding and immune drivers (e.g. complement and autoantibodies) in MMN uncover a clearer therapeutic opportunity, enabling companies to confidently expand beyond MG into an underrecognised but potentially high-value market?
- What defines the true biological window of intervention in GBS, and how can aligning immune modulation strategies to disease phase (rather than late-stage symptoms) improve clinical outcomes and prevent irreversible damage?
- How should evolving insights into MMN and GBS pathophysiology reshape trial design, from patient identification to endpoint selection, to ensure therapies demonstrate meaningful efficacy within the right population and timing?
Wednesday 22nd July 2026
Chair’s Closing Remarks
Thursday 23rd July 2026
Chair’s Opening Remarks
8:55 am
Thursday 23rd July 2026
Chair’s Closing Remarks & End of Conference
3:00 pm
